Navigation Links
Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine
Date:12/4/2007

NEW YORK, Dec. 4 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX: IMM) announced today that the Company has granted an exclusive license to BioAlliance Pharma SA (Euronext Paris - ticker code BIO) to commercialize Immtech's oral drug, pafuramidine maleate (pafuramidine), in Europe for the treatment of pneumocystis pneumonia (PCP) in AIDS patients and for the treatment of Human African trypanosomiasis, also known as African sleeping sickness. Pafuramidine is currently in Phase III clinical trials for these two indications. Immtech also granted to BioAlliance an option to commercialize pafuramidine in Europe for prevention and treatment of malaria in travelers.

Pursuant to the agreement, Immtech will receive an initial payment of $3 million from BioAlliance. An additional $13 million will be paid to Immtech as pafuramidine advances through European regulatory approval and pricing. Immtech will also receive additional payments based on sales milestones and significant double-digit royalties on sales. BioAlliance has an option to commercialize pafuramidine for malaria prophylaxis in Europe, and BioAlliance would contribute to funding clinical development costs. Additional regulatory, pricing, and sales milestone payments to Immtech and royalty payments based on sales would also be paid by BioAlliance.

"We are delighted to be collaborating with BioAlliance to launch pafuramidine in Europe," said Eric L. Sorkin, Chairman and Chief Executive Officer of Immtech. "BioAlliance's development and marketing expertise, as evidenced by the recent launch of Loramyc(R) in Europe for the treatment of HIV and cancer, demonstrate BioAlliance's proven capabilities in this market. We believe BioAlliance's valuabl
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Immtech to Present at The Bank of Montreal Healthcare Conference
2. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
5. National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
6. Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug
7. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
10. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
11. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 With the accelerated aging ... health expenditure as well as the improved medical ... diagnostic reagent industry has been developing quickly, especially ... 2013, Chinese in vitro diagnostics market size reached ... in vitro diagnostic reagents. , Read complete ...
(Date:7/30/2014)... Vycom announces the addition of Thermax PVC to ... Mutual (FM) 4910 fire propagation and smoke generation criteria ... tools, fume hoods, furniture and cabinetry. These criteria reduce ... used in electronic chip manufacturing. , Flametec ... workability and superior aesthetics. It is available in a ...
(Date:7/30/2014)...  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), is ... technologies are used to discover, develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... Vice President and Chief Financial Officer. Tom will ... technology operations for Dyadic and will succeed ...
(Date:7/30/2014)... July 30, 2014  AtheroNova Inc. (OTCBB: AHRO), ... development of compounds to safely regress atherosclerotic plaque ... that its partner, CardioNova, has accomplished first dosing ... with AtheroNova,s lead compound, AHRO-001.  This Phase 1b ... Phase 1 safety trial completed in February 2014, ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4
... 9 Boston Scientific,Corporation (NYSE: BSX ) ... has revised its Rating Outlook on the Company, ... long-term credit rating of,BB+., Fitch said the ... is making toward stabilizing its drug-eluting stent and ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ("PBI") ... (PNNL), the Harvard School of,Public Health (HSPH), the ... Drug Administration (FDA) presented data generated through the,use ... last week,s,(June 1-5) American Society for Mass Spectrometry,s ...
... Inc. (Nasdaq:,NUVA), a medical device company focused on developing ... today,that Kevin O,Boyle, Executive Vice President and Chief Financial ... Annual Growth Stock,Conference at the Four Season Hotel, Chicago, ... A live Web cast of the presentation will ...
Cached Biology Technology:Boston Scientific Welcomes Revised Outlook From Fitch Ratings 2Boston Scientific Welcomes Revised Outlook From Fitch Ratings 3Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO 2Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO 3Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO 4NuVasive to Present at William Blair 28th Annual Growth Stock Conference 2NuVasive to Present at William Blair 28th Annual Growth Stock Conference 3
(Date:7/30/2014)... published new research from Bjorn Brembs, professor of neurogenetics ... with a proof-of-concept figure allowing readers and reviewers to ... This represents an important leap forward for scientific publishing, ... quality of a scholarly output. , Figure 3 in ... and their code to F1000Research , and the ...
(Date:7/30/2014)... therapies for spinal cord injury (SCI), traumatic brain injury ... great deal has been learned over the past 30 ... factors that regulate axon growth, but this large body ... therapeutics. Prof. Lemmon and his team from University of ... root causes, but a consensus is emerging that one ...
(Date:7/30/2014)... a paper published online today in the journal ... researchers Evan Kodra and Auroop Ganguly found that while ... variability in temperature extremes. For instance, while each year,s ... averages will also tend to fall within a wider ... are currently being observed. This means that even as ...
Breaking Biology News(10 mins):F1000Research brings static research figures to life 2Big data confirms climate extremes are here to stay 2
... 11, 2013 Elsevier, a world-leading provider of scientific, ... launch of Journal of Forensic Radiology and Imaging ... the International Society of Forensic Radiology and Imaging (ISFRI). ... of forensic radiology and imaging, JOFRI aims ...
... Discovery , the flagship journal of the American Association ... American research centres, presents significant results in treating cancer ... This marks the first time that the therapeutic effect ... Barcelona, 11 February 2013. A study led by Dr ...
... By thinking of cells as programmable robots, researchers at Rice ... tiny blood vessels that feed the brain and help people ... Amina Qutub and her colleagues simulate patterns of microvasculature cell ... their lab. Eventually, they want to develop the ability to ...
Cached Biology News:Elsevier announces the launch of a new journal: Journal of Forensic Radiology and Imaging 2First-in-man study demonstrates the therapeutic effect of RNAi gene silencing in cancer treatment 2First-in-man study demonstrates the therapeutic effect of RNAi gene silencing in cancer treatment 3Rice University lab show how blood vessels regroup after stroke 2Rice University lab show how blood vessels regroup after stroke 3
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Pendrin (H-195)...
Request Info...
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Biology Products: